Antitumor agent, kit and method of treating cancer
AssigneesShizuoka Prefecture, Taiho Pharmaceutical Co., Ltd.
InventorSung Hwa Park
Life of this patent
Estimating the term…
Loading patent…
AssigneesShizuoka Prefecture, Taiho Pharmaceutical Co., Ltd.
InventorSung Hwa Park
Estimating the term…
Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer.
A method for treating cancer comprising co-administering to a mammal (1) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects.
Dependencies are inferred from the claim text.